Fayetteville

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Liver cirrhosis2 trials

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Akero Therapeutics, Inc4 trials

Running trials

• Recruiting

  A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

  NCT06528314· Phase 3· Akero Therapeutics, Inc· Source

  Contact: Akero Site 9227

• Recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  NCT06215716· Phase 3· Akero Therapeutics, Inc· Source

  Contact: Akero Site 9227

• Active, not recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT06161571· Phase 3· Akero Therapeutics, Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

  NCT05039450· Phase 2· Akero Therapeutics, Inc· Source